Gilead Signs Global Research Collaboration with Tango to Develop & Commercialize Targeted Immuno-Oncology Therapies

 Gilead Signs Global Research Collaboration with Tango to Develop &  Commercialize Targeted Immuno-Oncology Therapies

Gilead Signs Global Research Collaboration with Tango to Develop & Commercialize Targeted Immuno-Oncology Therapies

Shots:

  • Tango to get $50M upfront plus $1.7B as preclinical fees and milestone payments in addition to royalties in response Gilead has option to license WW rights to five targets developed from Tango’s genomics-based discovery platform
  • Additionally, Tango has option to co-develop and co-retain two program from the above five targets in the US & is eligible to receive royalties and milestones payments (ex the US). The profit and cost sharing will be done equally b/w the companies
  • The focus of the agreement is to develop next generation targeted immune therapies by combining Tango’s technology + Gilead’s drug discovery platform, for the treatment of cancer

Click here to read full press release/ article | Ref: Gilead | Image: Portfolio Third Rock Ventures

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post